NCT01704404

7 Days of TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease

A Phase 2 Study of the Pharmacodynamics, Safety and Tolerability, and Pharmacokinetics of Multiple Doses of TD-4208 for 7 Days in Subjects Diagnosed With Chronic Obstructive Pulmonary Disease

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 62 (actual)
• Sponsor: Mylan Inc. · Industry
• Sex: All
• Age: 40 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study will characterize the dose response of TD-4208 after 7 days of dosing in subjects with Chronic Obstructive Pulmonary Disease (COPD).

Conditions

• COPD

Interventions

Type	Name	Description
DRUG	TD-4208
DRUG	Placebo

Timeline

• Start date: 2012-12-01
• Primary completion: 2013-11-01
• Completion: 2013-12-01
• First posted: 2012-10-11
• Last updated: 2022-02-24
• Results posted: 2017-03-13

Locations

1 site across 1 country: New Zealand